AI-powered imaging solutions for early detection and structured management of lung diseases will be deployed
HCG Manavata Cancer Centre (HCGMCC) has announced a strategic partnership with health-tech innovator Qure.ai to implement cutting-edge AI-powered imaging solutions for early detection and structured management of lung diseases, including suspected lung cancer. Under this partnership, qXR (AI-enabled Chest X-ray) and qCT (AI-enabled Chest CT) will be deployed at the hospital, supported by qTrack – Qure.ai’s comprehensive disease tracking platform. The technology enables real-time risk identification and automated triaging to significantly improve the accuracy and speed of diagnosis.
The deployment is part of Qure.ai’s ongoing collaboration with Johnson & Johnson MedTech, aimed at democratising lung health by scaling AI-powered solutions across India.
“A 5 mm nodule missed today becomes stage-four cancer tomorrow. Qure.ai’s AI acts as our 24/7 digital sentinel, catching whispers of disease before symptoms scream. This collaboration allows us to expand the boundaries of what’s possible in early detection,” says Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director – KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik.
The hospital has also launched a dedicated Incidental Pulmonary Nodule (IPN) Clinic, positioning HCG Manavata Cancer Centre as a central hub in a hub-and-spoke model for the region. The clinic will ensure structured follow-up for high-risk imaging findings, facilitate timely intervention, and improve outcomes for patients, especially in early-stage lung cancer, where detection is often delayed.
